Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2966129 | 0.93 | PDE4B (0.87) | PDE4BPDE3A | |
| SCHEMBL13240900 | 0.92 | PDE4B (0.85) | PDE4BPDE3A | |
| SCHEMBL2966021 | 0.89 | PDE4B (0.80) | PDE4BPDE3A | |
| SCHEMBL2966019 | 0.86 | PDE4B (0.76) | PDE4BPDE3A | |
| SCHEMBL2961403 | 0.85 | PDE4B (0.74) | PDE4BPDE3A | |
| SCHEMBL2970220 | 0.84 | PDE4B (0.85) | PDE4BPDE3A | |
| SCHEMBL2960062 | 0.83 | PDE4B (1.00) | PDE4BPDE3A | |
| SCHEMBL2963833 | 0.83 | PDE4B (0.71) | PDE4BPDE3A | |
| SCHEMBL2968129 | 0.82 | PDE4B (0.73) | PDE4BPDE3A | |
| SCHEMBL2967640 | 0.82 | PDE4B (0.71) | PDE4BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763617-B2 | Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | claimed |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | claimed |
| US-12582809-B2 | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor | BT BIDCO, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3870261-B1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | BIORA THERAPEUTICS INC (US) | 2024-01-31 | — | — | EP | disclosed |
| EP-4309722-A2 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | Biora Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-116726361-A | Methods and devices for treating diseases with biologic therapeutic agents | 比奥拉治疗股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116726362-A | Methods and devices for treating diseases with biologic therapeutic agents | 比奥拉治疗股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230149315-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | GLAS USA LLC | 2023-05-18 | — | — | US | disclosed |
| CN-113348011-B | Method and apparatus for treating disease with biotherapeutic agents | 比奥拉治疗股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20230107927-A1 | METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS | FIRST WAVE BIO, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20160194319-A1 | PYRIDOPYRIMIDINE BASED DERIVATIVES AS POTENTIAL PHOSPHODIESTERASE 3 (PDE3) INHIBITORS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2016-07-07 | — | — | US | disclosed |
| US-9242982-B2 | Pyridopyrimidine based derivatives as potential phosphodiesterase 3 (PDE3) inhibitors and a process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-01-26 | — | — | US | disclosed |
| US-20140221651-A1 | PYRIDOPYRIMIDINE BASED DERIVATIVES AS POTENTIAL PHOSPHODIESTERASE 3 (PDE3) INHIBITORS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-08-07 | — | — | US | disclosed |
| US-7763617-B2 | Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-7763617-B2 | Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-7763617-B2 | Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582809-B2 | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor | PDE4A, PDE1A, PDE4B | PDE4B 3/4885PDE3A 11/4885 |
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | MUC1, SLC10A2, FABP2 | PDE4B 594/4885PDE3A 191/4885 |
| US-20140221651-A1 | PYRIDOPYRIMIDINE BASED DERIVATIVES AS POTENTIAL PHOSPHODIESTERASE 3 (PDE3) INHIBITORS AND A PROCESS FOR THE PREPARATION THEREOF | PDE3A, PDE3B, PDE5A | PDE4B 10/4885PDE3A 1/4885 |
| US-20160194319-A1 | PYRIDOPYRIMIDINE BASED DERIVATIVES AS POTENTIAL PHOSPHODIESTERASE 3 (PDE3) INHIBITORS AND A PROCESS FOR THE PREPARATION THEREOF | PDE3A, PDE3B, PDE5A | PDE4B 8/4885PDE3A 1/4885 |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | PDE5A, PDE3A, PDE3B | PDE4B 7/4885PDE3A 2/4885 |
| US-20230149315-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | MUC1, SLC10A2, FABP2 | PDE4B 594/4885PDE3A 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.